Reports Q3 revenue $184M, consensus $185.91M. “Orthofix has performed well and operated smoothly following the announcement of our management transition. The Company saw very strong growth across multiple business segments and product lines. Our complementary portfolio is driving even further incremental cross selling opportunities,” said Catherine Burzik, Chair of the Board and Interim Chief Executive Officer of Orthofix. “Sales momentum is strong, and we are laser focused on driving shareholder value via profitable growth and merger synergy realization. We expect the company to deliver much higher adjusted profits next year and to exit 2024 cash-flow positive. I am highly confident in the future of the company.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OFIX:
- Orthofix International (OFIX) Q3 Earnings Cheat Sheet
- Orthofix initiated with a Neutral at Roth MKM
- Orthofix announces510k clearance and full commercial launch of OsteoCove
- Needham biotechnology analysts to hold an analyst/industry conference call
- Orthofix updates SeaSpine merger, combined entity name to be announced
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue